Product class: Medicinal product with marketing authorization
Medicinal product class: Veterinary medicine
Name of medicinal product: Oncept IL-2
Active substances:
Feline interleukin-2 recombinant canarypox virus
Estonian, English, Latin
ATC code: QL03AX90
Dosage form: lyophilisate and solvent for suspension for injection
Legal status for supply*: Subject to medicinal prescription
Summary of product characteristics (SPC):
Package information leaflet (PIL): EST
Indication: Immunotherapy to be used in addition to surgery and radiotherapy in cats with fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement in order to reduce the risk of relapse and to increase the time to relapse (local recurrence or metastasis). This was demonstrated in a field trial over a period of 2 years.
Safety features: No
Marketing authorization holder: Boehringer Ingelheim Vetmedica GmbH 
Marketing authorization number: EU/2/13/150 
Marketing authorization issued on: 07 May 2013 
Marketing authorization expires on: Unlimited 
Marketing authorization procedure type: Centralised 
Assessment report:   
Package code Name of medicinal product Dosage form Package Legal status Reimbursements Reference price Last imported PƤritolumaa Additional information
1619164  Oncept IL-2  lyophilisate and solvent for suspension for injection  1annus 6TK  Prescription          lahusti 1 ml 
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription